Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Core Points - Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing novel radioimmunotherapy and antibody-based therapeutic products for cancer treatment [3] - Michael Rossi, the President and CEO of Y-mAbs, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 [1] - A live webcast of the presentation will be available on the company's investor relations website and archived for 30 days [2] Company Overview - Y-mAbs utilizes advanced technologies such as the Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform (PRIT) and bispecific antibodies generated through the Y-BiClone platform [3] - The company's product pipeline includes DANYELZA® (naxitamab-gqgk), the first FDA-approved treatment for relapsed or refractory high-risk neuroblastoma in patients who have had a partial response, minor response, or stable disease to prior therapy [3]